Researchers at Osaka University reveal how a regulatory molecule ensures an appropriate supply of blood cells while avoiding the excessive proliferation associated with conditions like leukemia OSAKA UNIVERSITY Osaka, Japan – The body needs to create a continuous supply of blood cells to enter circulation. Blood cells have a wide variety of functions ranging from supplying oxygen to tissues, fighting infections, and enabling the blood to...
Tag: <span>Leukemia</span>
Post
Researchers identify experimental Immunotherapy approach to target acute myeloid leukemia
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a potential way to target a subtype of acute myeloid leukemia (AML) using chimeric antigen receptor (CAR) T-cell therapy, a form of immunotherapy in which patients’ immune cells are genetically engineered to recognize and track their cancer. Credit: CC0 Public Domain At the 60th...
Post
An errant editing enzyme promotes tumor suppressor loss and leukemia propagation
Writing in the January 3 issue of Cancer Cell, researchers at University of California San Diego School of Medicine report that detection of “copy editing” by a stem cell enzyme called ADAR1, which is active in more than 20 tumor types, may provide a kind of molecular radar for early detection of malignancies and represent...
Post
First-in-class YEATS inhibitors that show promise for leukemia treatment
A research team led by Dr. Xiang David Li from the Department of Chemistry at The University of Hong Kong (HKU), in collaboration with scientists from Tsinghua University in China, The Rockefeller University, and The University of Texas MD Anderson Cancer Center in the United States, developed the first chemical inhibitors against a novel therapeutic...
Post
Delving where few others have gone, leukemia researchers open new path
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could improve AML survival rates, which have not budged in recent years. The gene, known as EVI1, rewires the entire panoply...
Post
FDA approves novel treatment for hairy cell leukemia
(HealthDay)—Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday. Lumoxiti, a CD22-directed cytotoxin, was approved for adults who have had at least two prior therapies for the disease. The FDA granted this application Fast Track and Priority Review designations. Lumoxiti also...
Post
Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia
Clinical trials at University of Colorado Cancer Center and elsewhere now result in the drug ivosidenib earning approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Ivosidenib, an oral, targeted inhibitor of the IDH1...
Post
FDA approves new leukemia drug from Agios, a first-in-class treatment
By KATE SHERIDAN — STAT @sheridan_kate and JONATHAN SALTZMAN — BOSTON GLOBEJULY 20, 2018 The Food and Drug Administration on Friday approved the first drug in a brand-new class of treatments for acute myeloid leukemia. The drug, ivosidenib — developed by Cambridge-based Agios Pharmaceuticals— is a once-daily pill that might replace chemotherapy for some people with refractory or...
Post
Clinical trials show promise in leukemia
July 10, 2018 by Anna Williams, Northwestern University Two drugs that target different mutations showed encouraging results in treating leukemia, according to recent clinical trials published in the New England Journal of Medicine (NEJM) and The Lancet Oncology. Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: Wikipedia Jessica Altman, MD, ’07 GME, associate professor...
Post
New epigenetic drug against Mantle Cell Lymphoma
New epigenetic drug against Mantle Cell Lymphoma A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical ResearchInstitute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of Barcelona, presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL), a...